Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
2.480
-0.040 (-1.59%)
Jun 26, 2025, 4:00 PM - Market closed

Company Description

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel.

It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis.

The company also provides contract development and manufacturing organization services to biotech companies.

It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody.

The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.

Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics logo
Country Israel
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Amir Reichman

Contact Details

Address:
Jerusalem BioPark, 2nd floor
Jerusalem
Israel
Phone 972 8 930 2529
Website scinai.com

Stock Details

Ticker Symbol SCNI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001611747
CUSIP Number 09073Q204
ISIN Number US09073Q2049
SIC Code 2836

Key Executives

Name Position
Amir Reichman M.B.A., M.Sc. Chief Executive Officer and Director
Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer
Dr. Dalit Weinstein Fischer Ph.D. Chief Technology Officer
Dr. Tamar Ben-Yedidia Ph.D. Chief Scientist
Merav Kamensky Head of Quality Control
Dr. Naama Adi Hen Head of Quality Asurance
Alona Tal Head of Business Administration

Latest SEC Filings

Date Type Title
Jun 12, 2025 6-K Report of foreign issuer
Jun 5, 2025 424B3 Prospectus
Jun 5, 2025 6-K Report of foreign issuer
Jun 2, 2025 6-K Report of foreign issuer
May 15, 2025 EFFECT Notice of Effectiveness
May 12, 2025 POS AM Post-Effective amendments for registration statement
May 7, 2025 20-F Annual and transition report of foreign private issuers
Apr 29, 2025 NT 20-F Notification of inability to timely file Form 20-F
Mar 27, 2025 6-K Report of foreign issuer
Mar 26, 2025 SCHEDULE 13G Filing